FOAMIX - DAILY CHART
Foamix Pharmaceuticals its gathering the attention of investors around the reporting of worse than expected earnings with an EPS of -0.35, representing -2.94% of the forecasted. The company also announced the Merging with Menlo Therapeutics (MNLO) focused on the development and commercialization of therapeutics for dermatologic indications. These news can imply an increase in volatility on the asset and further investors' especulation.
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.